Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study
- Inés Oliveira1,2,
- Andreas Andersen1,
- Alcino Furtado1,
- Candida Medina3,
- David da Silva3,
- Zacarias J da Silva1,4,
- Peter Aaby1,5,
- Alex Lund Laursen6,
- Christian Wejse6,7,
- Jesper Eugen-Olsen2,
- for the Bissau HIV cohort study group
- 1Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau
- 2Clinical Research Centre, Copenhagen University, Copenhagen, Denmark
- 3National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau
- 4National Public Health Laboratory, Bissau, Guinea-Bissau
- 5Statens Serum Institute, Copenhagen, Denmark
- 6Department of Infectious Diseases, Skejby, Aarhus, University Hospital, Aarhus, Denmark
- 7Centre for Global Health (GloHAU), Institute for Public Health, Aarhus University, Aarhus, Denmark
- Correspondence to Dr Jesper Eugen-Olsen;
- Received 31 May 2012
- Accepted 26 August 2012
- Published 14 November 2012
Background Decisions about when to start an antiretroviral therapy (ART) are normally based on CD4 cell counts and viral load (VL). However, these measurements require equipment beyond the capacity of most laboratories in low-income and middle-income settings. Thus, there is an urgent need to identify and test simple markers to guide the optimal time for starting and for monitoring the effect of ART in developing countries.
Objectives (1) To evaluate anthropometric measurements and measurement of plasma-soluble form of the urokinase plasminogen activator receptor (suPAR) levels as potential risk factors for early mortality among HIV-infected patients; (2) to assess whether these markers could help identify patients to whom ART should be prioritised and (3) to determine if these markers may add information to CD4 cell count when VL is not available.
Design An observational study.
Setting The largest ART centre in Bissau, Guinea-Bissau.
Participants 1083 ART-naïve HIV-infected patients.
Outcome measures Associations between baseline anthropometric measurements, CD4 cell counts, plasma suPAR levels and survival were examined using Cox proportional hazards models.
Results Low body mass index (BMI≤18.5 kg/m2), low mid-upper-arm-circumference (MUAC≤250 mm), low CD4 cell count (≤350 cells/μl) and high suPAR plasma levels (>5.3 ng/ml) were independent predictors of death. Furthermore, mortality among patients with low CD4 cell count, low MUAC or low BMI was concentrated in the highest suPAR quartile.
Conclusions Irrespective of ART initiation and baseline CD4 count, MUAC and suPAR plasma levels were independent predictors of early mortality in this urban cohort. These markers could be useful in identifying patients at the highest risk of short-term mortality and may aid triage for ART when CD4 cell count is not available or when there is shortness of antiretroviral drugs.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.